Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia

Racquel D. Innis-Shelton, Randall S. Davis, Lawrence Lamb, Shin Mineishi

Research output: Contribution to journalReview articlepeer-review


With the growing complexity of treatment options for chronic lymphocytic leukemia (CLL) and variables that influence the underlying biology of this disease, providing allogeneic stem cell transplant (alloSCT) to appropriate candidates poses a challenge for transplant physicians. Novel small molecule inhibitors hold unprecedented promise for poor-risk subgroups, which will likely alter decision-making and referral patterns for transplant. In this review, we analyze what is known and may still remain true about indications for transplant based on outcomes reported in the literature recently and over the last decade.

Original languageEnglish (US)
Pages (from-to)1626-1635
Number of pages10
JournalLeukemia and Lymphoma
Issue number6
StatePublished - Jun 1 2015

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this